Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032772 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4ECXCR2L3MBTL1PKM | |
| SCHEMBL16592116 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EL3MBTL1PKMRAB9A | |
| SCHEMBL4492296 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1PKMRAB9A | |
| SCHEMBL3925637 | 0.78 | KMT2A (0.49) | ALDH1A1KDM4ERAB9ASMN1; SMN2KMT2A | |
| SCHEMBL10685404 | 0.78 | CXCR2 (0.64) | ALDH1A1KDM4ECXCR1CXCR2L3MBTL1 | |
| SCHEMBL413122 | 0.77 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2585379 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1PKMRAB9A | |
| SCHEMBL7797891 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1PKMRAB9A | |
| SCHEMBL20381801 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KDM4EL3MBTL1PKMRAB9A | |
| SCHEMBL5717582 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KDM4EL3MBTL1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 455/4885KDM4E 674/4885CXCR1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.